1B. Sc. Pharmacy, Department of Pharmacology and Therapeutics, College of Medicine, University of Kufa
2ChB MSC, PhD Pharmacology and Therapeutics, Assistant Professor, Department of Pharmacology and Therapeutics, College of Medicine, University of Kufa
3PhD genetic engineering and biotechnology, Assistant Professor, Cancer Research Unit, College of Medicine, University of Kufa
4Lecturer, Department of Pharmacology and Toxicology, College of medicine, University of Babylon
Online published on 6 April, 2019.
MYC modifies the expression of many genes, and the deregulated expression of C-MYC represents a hallmark feature of cancer because most, if not all, human cancers have a deregulation in C-MYC and associated with poor prognoses. The Primary human colorectal carcinomas were enormously associated with C-MYC overexpression. This study involved an assessment of the cytotoxic effects of PAX2M, a direct C-MYC oncoprotein blocking agent, in a colorectal cancer cell line, and the evaluation of its safety in the normal tissue cell line. The results indicate a significant reduction in the cells viability at the dose-dependent fashion moreover, PAX2M displayed a lower toxicity in normal cells The investigational agent PAX2M described in this study that directly targets C-MYC oncoprotein is likely to be a promising therapeutic agent for colorectal cancer treatment.
C-MYC targeting therapy, colorectal cancer, antineoplastic drugs, crystal violet assay, cell line
